You are here: Industry Insights > Market News > Marksons Pharma voluntarily recalls a batch of Metformin XR tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Marksons Pharma voluntarily recalls a batch of Metformin XR tablets

expresspharmaJune 09, 2020

Tag: Marksons Pharma , metformin , NDMA

Favorites

Marksans Pharma has issued a voluntary recall of one batch of Metformin Extended-Release Tablets USP 500 mg (11279 bottles, Lot No. XP9004), informed the company through a statement.

It is due to the detection of NDMA as a matter of abundant precaution.

Metformin Extended-Release Tablets USP500 mg is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.

Previous:Gland Pharma launches of the first non-frozen ready-to-use Bivalirudin

Next:US FDA grants Lupin’s Mexiletine Orphan Drug Designation

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Marksons Pharma voluntarily recalls a batch of Metformin XR tablets | Pharmasources.com

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.

Marksons Pharma voluntarily recalls a batch of Metformin XR tablets

Related News

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

You may like